Emergent BioSolutions (EBS) Common Equity (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Common Equity of $523.1 million for Q1 2026, down 5.36% year-over-year from $552.7 million in Q1 2025, and little changed quarter-over-quarter from $522.6 million in Q4 2025.
Emergent BioSolutions (EBS) Common Equity (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Common Equity history runs 17 years deep, the most recent figure standing at $523.1 million for Q1 2026.
- In Q1 2026, Common Equity fell 5.36% year-over-year to $523.1 million; the TTM figure through Mar 2026 stood at $523.1 million (down 5.36% YoY), while the FY2025 annual figure was $522.6 million, up 8.24% from the prior year.
- Common Equity for Q1 2026 stood at $523.1 million, roughly flat from $522.6 million in the prior quarter.
- The five-year high for Common Equity was $1.6 billion in Q1 2022, with the low at $386.3 million in Q2 2024.
- The 5-year median for Common Equity is $649.3 million (2023), against an average of $833.1 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity plunged 59.66% in 2024, then jumped 38.8% in 2025.
- Emergent BioSolutions' Common Equity stood at $1.4 billion in 2022, then slumped by 53.21% to $649.3 million in 2023, then decreased by 25.64% to $482.8 million in 2024, then increased by 8.24% to $522.6 million in 2025, then rose by 0.1% to $523.1 million in 2026.
- Business Quant data shows EBS's Common Equity at $523.1 million in Q1 2026, $522.6 million in Q4 2025, and $582.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 341.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 341.40 Mn |
| Mar 31, 2026 | 523.10 Mn |
| Dec 31, 2025 | 522.60 Mn |
| Sep 30, 2025 | 582.50 Mn |
| Jun 30, 2025 | 536.20 Mn |
| Mar 31, 2025 | 552.70 Mn |
| Dec 31, 2024 | 482.80 Mn |
| Sep 30, 2024 | 508.40 Mn |
| Jun 30, 2024 | 386.30 Mn |
| Mar 31, 2024 | 663.90 Mn |
| Dec 31, 2023 | 649.30 Mn |
| Sep 30, 2023 | 697.20 Mn |
| Jun 30, 2023 | 957.70 Mn |
| Mar 31, 2023 | 1.20 Bn |
| Dec 31, 2022 | 1.39 Bn |
| Sep 30, 2022 | 1.43 Bn |
| Jun 30, 2022 | 1.51 Bn |
| Mar 31, 2022 | 1.57 Bn |
| Dec 31, 2021 | 1.61 Bn |
| Sep 30, 2021 | 1.52 Bn |